Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients
Growing evidence suggests that the patient’s immune response may play a major role in the long-term efficacy of antibody therapies of follicular lymphoma (FL). Particular long-lasting recurrence free survivals have been observed after first line, single agent rituximab or after radioimmunotherapy (RIT). Rituximab maintenance, furthermore, has a major efficacy in prolonging recurrence free survival after chemotherapy. On the other hand, RIT as a single step treatment showed a remarkable capacity to induce complete and partial remissions when applied in recurrence and as initial treatment of FL or given for consolidation. These clinical results strongly suggest that RIT combined with rituximab maintenance could stabilize the high percentages of patients with CR and PR induced by RIT. While the precise mechanisms of the long-term efficacy of these 2 treatments are not elucidated, different observations suggest that the patient’s T cell immune response could be decisive. With this review, we discuss the potential role of the patient’s immune system under rituximab and RIT and argue that the T cell immunity might be particularly promoted when combining the 2 antibody treatments in the early therapy of FL.
1. Long-Term Complete Remissions of FL Have Been Reported after Either RIT or Rituximab Treatment
Advanced stage follicular lymphoma (FL) cannot be cured by standard chemotherapy . In the frequently slow evolution of the disease, FL tends to become less responsive to chemotherapy, remissions lasting shorter time or the disease transforms to higher grade lymphoma. In recent years, it has been shown repeatedly that allogeneic hematopoietic stem cells transplantation (HSCT) can induce a plateau of tumor free survival and has a curative potential [2–4], suggesting that donor T cells bear the potential to cure FL patients .
The first, highly efficient anti-CD20 radioimmunotherapy (RIT) has been published in 1993 [6, 7] and single agent rituximab (Mabthera, Rituxan, Roche Ltd, Genentech) treatments were published a few years later [8–11]. Long-term complete remissions (CR) lasting 8 years or more have since been reported after single agent rituximab as well as after RIT [9, 10, 12–15]. These sustained remissions might be a first indication of the curative potential of the 2 antibody based treatments.
There is increasing evidence that the patient’s T cells could be particularly involved in these long-term responses, as recently postulated in a letter to the editor . The combination of the 2 treatments, as discussed here, with the particular aim to preserve, stimulate, and study the patient’s T cell response would appear attractive notably when being initiated as first line or early treatment of FL.
2. The Patient’s Immune Response May Be Relevant to Long-Term Tumor Control of FL
The tumor microenvironment shows remarkable adaptations in FL . Tumor cells interact with stromal cells allowing the promotion of tumor growth [18–20]. Cytotoxic T lymphocytes were shown to have a tumor controlling potential, but, once they are present in the tumor microenvironment, they may be inhibited by regulatory T and/or B cells [21–25] or exhausted as shown in melanoma  and lymphoma .
Conversely, immune response signatures have identified tumor infiltrating T cells, monocytes, and dendritic cells as being predictive of survival of FL . RT-PCR based gene expression profiling results were in agreement with these observations . Interestingly, high numbers of tumor infiltrating FOXP3 positive regulatory T cells were also predictive of improved overall survival . The nature as well as the potential heterogeneity of regulatory T cells remains, however, controversial [31, 32]. Recently, follicular Th cells in the tumor microenvironment have also been implicated in promoting immunosuppression . Thus, contradicting roles have been observed for tumor infiltrating stromal cells .
Under rituximab treatment elimination of regulatory B cells (Breg, B10) could be an explanation for the observation of favorable T cell responses [24, 34]. Different groups have also studied at the preclinical and clinical level the efficacy of blocking T-cell inhibitory receptors . Anti-CTLA-4 [25, 36] and anti-PD-1 [37, 38] treatments showed interesting results in animals and lymphoma patients. Possibly, this approach may become increasingly successful, similar to the progress in patients with melanoma, lung, and kidney cancers [39–42].
Allogeneic HSCT provides the patient with the immunological graft antilymphoma effect that is not necessarily linked with a graft versus host reactivity . It leads to a plateau in tumor free survival and provides a chance of cure in advanced stage FL [2–4]. In nonmyeloablative allogeneic HSCT, the potential curative response of chemorefractory patients who had a conditioning regimen including 90Y-ibritumomab, fludarabine, and cyclophosphamide was interpreted as likely being related to the graft versus lymphoma effect, facilitated by an improved initial disease control, provided by radioimmunotherapy (RIT) .
Weiner et al. highlighted 3 potential mechanisms for induction of a tumor-antigen-specific immune response , namely, antibody dependent cellular cytotoxicity (ADCC), antibody-targeted cross-presentation of tumor antigens , and triggering of the anti-idiotypic antibodies . Regarding the latter mechanism, the anti-idiotype antibody response of FL patients after idiotype vaccination was shown to correlate with better overall survival . Such a “vaccinal effect” resulting in the induction of a specific anti-idiotype T cell response has also been observed after rituximab treatment .
Different preclinical studies further highlighted the potential role of rituximab alone or in combination with vaccines in immune stimulation leading to long-term protection in lymphoma models [48–50]. Stimulation of CD8 T cells has been shown to provide long-lasting antitumor immune protection in syngeneic mouse lymphoma [51–53]. Toll-like receptor stimulation in combination with rituximab treatment has been explored in first clinical studies [54, 55].
3. Single Agent Rituximab Treatment Is Able to Stimulate T Cell Responses
Single agent rituximab treatment has been studied in different trials [8–11]. Rituximab is particularly attractive due to its capacity to treat B lymphoma while totally sparing T cells . Rituximab maintenance has been shown to be highly efficient after the second line R-chemotherapy but is currently also proposed after the first line R-chemotherapy with a significant benefit shown in the PRIMA trial . Long-lasting complete responses (CR) have been observed in FL patients responding (67%) in an early SAKK trial to initial, single agent rituximab. 45% of the responding patients after first line rituximab reached 8 years continued CR when randomized into the rituximab maintenance arm , even though rituximab maintenance in this early study consisted of only 4 supplemental antibody injections administered every 2nd month. Long-term responses were also described after rituximab standard treatment alone .
Upon rituximab treatment of lymphoma, activation of NK cells occurs  and presence of high numbers of CD4 and CD8 T cells has been shown as being favorable . CD4 T helper cells, CD8 T cells, and NK cells remained stable under rituximab treatment while helper and NK cells were significantly associated with response and EFS, respectively . A lymphoma idiotype-specific T cell response was described for FL patients treated by rituximab alone, suggesting that this therapy might also act as a vaccine . Tumor-infiltrating T-helper cells are repressed in the tumor environment as compared with the same population in normal lymph nodes, however, it was shown that they retain their polyfunctional potential to respond to vaccinal stimulation . These observations clearly indicate that rituximab can stimulate the patient’s antilymphoma T cell response.
Possibly, another set of T cells, the γδ T cells may be involved in FL immunity [61, 62]. Rituximab could potentially play an enhancing role with regard to these cells as well [63, 64]. Furthermore, under combined treatment with rituximab and interferon-α , the presence of CD4+ and CD8+ T cells was shown to be favorable while in a different study interferon was able to abrogate the negative effect of IL4 on immune cells .
Elimination of regulatory B cells (Breg, B10) could be a further explanation to the observation of T cell responses under rituximab treatment [24, 34]. In mice, such Il-10 producing B10 cells inhibited lymphoma clearance during anti-CD20 immunotherapy. Stimulation of effector T cells with a TLR3 agonist was able to overcome the negative regulatory effects of B10 cells . Since B10 cells are at least partially eliminated by the anti-CD20 therapy, the B cell mediated immunesuppression may be abrogated or at least weakened.
4. Single Agent or Consolidation RIT Induces Long-Term CR at High Frequency
RIT has been shown to be an effective single agent therapy at conventional, nonmyeloablative dosing as well as in high dose therapy both in patients in relapse [6, 7, 66] and as an initial treatment [12, 67]. RIT consolidation after chemotherapy was shown to convert high numbers of partial remissions (PR) into CR and to provide prolonged progression free survival [68, 69], the latter being also confirmed at the molecular level [14, 70]. Regarding the upfront, single agent RIT with 131I-tositumomab , a 40% 10-year relapse free survival was reported . While anti-CD20 directed RIT also reduced B cells, T cell responses in these patients appeared to be preserved . We observed similarly long-lasting CR in a small series of relapsed indolent lymphoma patients treated between 1999 and 2001 with 131I-tositumomab , with 6 out of 12 patients showing continued CR at currently 12 years after RIT .
The particular high efficacy of RIT is probably not explained by the delivered radiation dose or by the 2 injections of anti-CD20 antibody given at reduced dose. Rather, the combination of both may be important. Indeed, it has been shown that irradiation can contribute to the induction of durable antitumor response in mouse models of lymphoma [52, 53]. It seems thus reasonable to hypothesize that the long-term efficacy of RIT is dependent on the activation and/or the functional preservation of the patient’s T cell antilymphoma response [12, 13]. Furthermore, the fact that the two approved anti-CD20 antibodies, tositumomab, and ibritumomab are of murine origin implies that the tumor cells are targeted with murine antigens, which can be recognized in their processed form by the patient’s T lymphocytes  via cross-presentation by antigen presenting cells, possibly together with antigens from dying tumor cells . CRs induced by RIT might liberate the patient’s T cells immunity from the immunosuppressive state imposed by live tumor masses  and Breg cells .
5. The Combination of Two Efficient Antibody Based Treatments May Limit Toxicity While the Long-Term Application (Maintenance) of Rituximab Should Favor the Development of an Immune Response
Major efforts in cancer treatment are currently directed into development of immunotherapy. In this respect, one might consider rituximab treatment as a lucky punch since rituximab treatment is efficient in patients, has moderate side effects, and has been shown to activate NK cells . Rituximab can have a vaccination effect inducing anti-idiotype T cell responses , and rituximab treatment alone is able to lead to long-lasting CR in FL patients . While the underlying mechanisms of the efficacy of rituximab are not yet clearly elucidated, it might well be multifunctional beyond T cells responses.
There are different reasons to combine RIT with rituximab maintenance. First, long-term results have been described for both treatments. Both treatments are of moderate toxicity and present a favorable potential of immune response triggering. RIT tumor bulk reduction is known to be highly efficient and could thus potentially reduce tumor mediated immunesuppression. RIT in combination with a long-term treatment, such as rituximab maintenance known to trigger the immune system, could also have a higher chance to build up a robust antitumor immune response and lead to longer recurrence free survival.
We hypothesize that the patient’s T cells would mediate the long term efficacy of rituximab and RIT. This hypothesis is only supported by indirect evidence of observations in patients and preclinical studies. Nevertheless, different studies have shown that rituximab can stimulate the patient’s T cells and have a vaccination effect while preclinical studies have shown that such effects can be decisive for cure in syngeneic mouse models. In that sense the hypothesis of a major T cell involvement in antibody treatment of FL joins other effects of rituximab that is clearly able to elicit direct apoptosis, ADCC, CDC, or opsonization, although it remains to be determined which of these mechanisms are decisive in patients. Regarding RIT, we argue that the radiation dose given to tumor with nonmyeloablative RIT and the 2 modest amounts of unlabeled antibody are most likely insufficient to explain its long-term efficacy when given as monotherapy upfront  or in relapse  of FL or indolent lymphoma. These long-term efficacies of RIT and rituximab in indolent lymphoma, a disease that cannot be cured in its advanced form by conventional treatment, prompt the search of different mechanisms of efficacy than the common ones.
Induction R-chemotherapy such as R-CVP, R-CHOP, R-MCP, and R-CHVP+I has been studied in large, randomized phase III trials in comparison with chemotherapy alone and has shown the advantage of adding rituximab to chemotherapy leading to improved PFS and frequently also OS [74–77], as recently discussed . Adding 2-year rituximab maintenance to such induction therapy was shown in a large phase III trial to improve PFS . Two recent phase III trials showed at least a similar efficacy for combined R-bendamustin treatment compared with R-CHOP [79, 80].
In view of the particular high and reliable efficacy of adding rituximab to different chemotherapies and further using it in maintenance, it is intriguing that maintenance treatment with anti-CD20 antibodies has not yet been evaluated in combination with RIT, possibly because RIT and rituximab are developed with different perspectives. An ongoing phase II study (NCT00770224) piloted by SWOG investigates the combined approach of R-CHOP induction chemotherapy followed by 131I-tositumomab consolidation and 4-year rituximab maintenance. First, results of a similar front line study combining R-CHOP followed by 90Y-radioimmunotherapy and maintenance rituximab over 2 years showed a sustained immune response with regard to T cell counts and memory immune responses while B cells were repressed . A high number of long-term molecular remissions in FL patients were reported in that study as well .
Radioimmunotherapy in the upfront setting has shown a remarkable capacity to induce high numbers of long-lasting CR. While R-CHOP combined with rituximab maintenance is currently a well-established upfront treatment, the combination of RIT with rituximab has never been studied. RIT is frequently seen as an alternative therapy to rituximab [82, 83]. This is also the case in a new randomized study that compares rituximab treatment with 131I-tositumomab therapy in relapsed FL patients (NCT00078598). However, rituximab treatment is a unique biological treatment with minor toxicity given under R-chemotherapy and in maintenance [84–87]. Clearly, RIT as a single step therapy involves a different therapeutic mechanism than rituximab maintenance. Furthermore, RIT presents the unique capacity of inducing high numbers of CR and of converting PR into CR when used in consolidation. This induction of CR notably may be important for the recovery of an effective T cell response since large tumors are able to inhibit the functioning of T cells [88–91].
Different studies have shown that therapeutic options for FL remain open after RIT, including as well collection and transplantation of HSCT . Furthermore, large studies have shown that MDS incidence is not increased after RIT [93, 94] but might rather be related to combination with preceding chemotherapies, particularly when these include fludarabine [95, 96].
Based on the hypothesis that a preserved or stimulated T cell response mediates long-term CR of FL, we argue that the unique capacity of RIT of inducing high numbers of long-lasting CR by its own, particularly when used upfront [12, 13], would merit to be evaluated in combination with maintenance by rituximab or another anti-CD20 antibody [97–99], possibly double antibody treatment [100, 101] or with adjunction of interferon-α . Such combinations may have only moderate toxicity for the patient himself and his T cells and may be most beneficial in previously untreated patients.
Further insight should be obtained by direct monitoring of the patient’s lymphoma specific T cells in RIT studies combined with rituximab maintenance. In parallel, other components of the immune system should also be analyzed, particularly B cells, to determine to which degree they remain repressed over prolonged periods after rituximab treatment, as suggested already from the early single agent rituximab study SAKK 35/98  and others . One could hypothesize that the patient’s T cell response would possibly be able to eradicate or at least control FL progenitor cells under such a combination of RIT with rituximab , a hypothesis supported by the observation of long-term CR after single agent rituximab and single agent RIT.
We would expect that the combination of RIT with anti-CD20 antibody maintenance in the early treatment of FL has the potential to be most efficient due to the preservation or/and stimulation of the patient’s antitumor T cells response. The addition of anti-PD-1 or anti-CTLA-4 antibodies may further enhance immune responses by reducing inhibitory pathways and regulatory cells. Indeed, consistent and repeated T cell stimulation may be achieved by RIT with its capacity to induce high numbers of CR, combined with rituximab maintenance capable of maintaining such CR. This approach may therefore be well suited as novel and readily feasible perspective towards potential cure of FL.
|HSCT:||Hematopoietic stem cells transplantation|
|RT-PCR:||Real-time polymerase chain reaction|
|ADCC:||Antibody dependent cellular cytotoxicity|
|CDC:||Complement dependent cytotoxicity|
|SAKK:||“Schweizerische Arbeitsgemeinschaft für klinische Krebsforschung” (Swiss Society for Clinical Cancer Research)|
|R-CVP:||Rituximab, cyclophosphamide, vincristine, and prednisone|
|R-CHOP:||Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone|
|R-MCP:||Rituximab-mitoxantrone, chlorambucil, and prednisolone|
|R-CHVP+I:||Rituximab, cyclophosphamide, doxorubicin, etoposide, and prednisolone plus interferon alfa-2a|
|EFS:||Event free survival|
|PFS:||Progression free survival|
Franz Buchegger and Daniel E. Speiser initiated the writing of this review. Franz Buchegger, Steven M. Larson, Jean-Pierre Mach, Yves Chalandon, Pierre-Yves Dietrich, Anne Cairol, John O. Prior, Pedro Romero, and Daniel E. Speiser then discussed, contributed further evidence, and corrected the paper. All authors approved the final version of the paper.
Yves Chalandon and Pierre-Yves Dietrich have received financial support from Roche Pharmaceutical for formation congresses and participation in board meetings. The other authors declare that there is no conflict of interests.
C. Ujjani and B. D. Cheson, “The optimal management of follicular lymphoma: an evolving field,” Drugs, vol. 73, no. 13, pp. 1395–1403, 2013.View at: Google Scholar
I. F. Khouri, R. M. Saliba, W. D. Erwin et al., “Nonmyeloablative allogeneic transplantation with or without (90)yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results,” Blood, vol. 119, pp. 6373–6378, 2012.View at: Google Scholar
P. J. Bierman, J. W. Sweetenham, F. R. Loberiza Jr. et al., “Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation: the Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation,” Journal of Clinical Oncology, vol. 21, no. 20, pp. 3744–3753, 2003.View at: Publisher Site | Google Scholar
M. Ghielmini, S. H. Schmitz, S. B. Cogliatti et al., “Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule,” Blood, vol. 103, no. 12, pp. 4416–4423, 2004.View at: Publisher Site | Google Scholar
P. Colombat, N. Brousse, G. Salles et al., “Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up,” Annals of Oncology, vol. 23, pp. 2380–2385, 2012.View at: Google Scholar
T. E. Witzig, A. M. Vukov, T. M. Habermann et al., “Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group,” Journal of Clinical Oncology, vol. 23, no. 6, pp. 1103–1108, 2005.View at: Publisher Site | Google Scholar
M. S. Kaminski, M. Tuck, J. Estes et al., “Tositumomab and Iodine I-131 Tositumomab for previously untreated, advanced-stage, follicular lymphoma: median 10 year follow-up results,” Blood, vol. 114, p. 3759, 2009, (Abstract).View at: Google Scholar
L. Goff, K. Summers, S. Iqbal et al., “Quantitative PCR analysis for Bcl-2/IgH in a phase III study of yttrium-90 ibritumomab tiuxetan as consolidation of first remission in patients with follicular lymphoma,” Journal of Clinical Oncology, vol. 27, no. 36, pp. 6094–6100, 2009.View at: Publisher Site | Google Scholar
F. Buchegger, J. P. Mach, O. W. Press et al., “Improving the chance of cure of follicular lymphoma by combining immunotherapy and radioimmunotherapy based on anti-CD20 antibodies?” Annals of Oncology, vol. 24, pp. 1948–1949, 2013.View at: Google Scholar
B. E. Wahlin, B. Sander, B. Christensson et al., “Entourage: the immune microenvironment following follicular lymphoma,” Blood Cancer Journal, vol. 2, p. e52, 2012.View at: Google Scholar
R. Kridel, L. H. Sehn, and R. D. Gascoyne, “Pathogenesis of follicular lymphoma,” Journal of Clinical Investigation, vol. 122, pp. 3424–3431, 2012.View at: Google Scholar
L. Li, J. Cole, and D. A. Margolin, “Cancer stem cell and stromal microenvironment,” The Ochsner Journal, vol. 13, pp. 109–118, 2013.View at: Google Scholar
A. Marabelle, H. Kohrt, I. Sagiv-Barfi et al., “Depleting tumor-specific Tregs at a single site eradicates disseminated tumors,” Journal of Clinical Investigation, vol. 123, pp. 2447–2463, 2013.View at: Google Scholar
S. S. Dave, G. Wright, B. Tan et al., “Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells,” The New England Journal of Medicine, vol. 351, pp. 2159–2169, 2004.View at: Google Scholar
S. Rawal, F. Chu, M. Zhang et al., “Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment,” The Journal of Immunology, vol. 190, pp. 6681–6693, 2013.View at: Google Scholar
J. H. Myklebust, J. M. Irish, J. Brody et al., “High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells,” Blood, vol. 121, pp. 1367–1376, 2013.View at: Google Scholar
P. Armand, A. Nagler, E. A. Weller et al., “Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial,” Journal of Clinical Oncology, 2013.View at: Publisher Site | Google Scholar
F. S. Hodi, S. J. O'Day, D. F. McDermott et al., “Improved survival with ipilimumab in patients with metastatic melanoma,” The New England Journal of Medicine, vol. 363, pp. 711–723, 2010.View at: Google Scholar
J. D. Wolchok, H. Kluger, M. K. Callahan et al., “Nivolumab plus ipilimumab in advanced melanoma,” The New England Journal of Medicine, vol. 369, pp. 122–133, 2013.View at: Google Scholar
S. L. Topalian, F. S. Hodi, J. R. Brahmer et al., “Safety, activity, and immune correlates of anti-PD-1 antibody in cancer,” The New England Journal of Medicine, vol. 366, pp. 2443–2454, 2012.View at: Google Scholar
O. Hamid, C. Robert, A. Daud et al., “Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma,” The New England Journal of Medicine, vol. 369, pp. 134–144, 2013.View at: Google Scholar
A. Lask, E. Ophir, N. Or-Geva et al., “A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cells,” Blood, vol. 121, pp. 3033–3040, 2013.View at: Google Scholar
S. P. Hilchey, O. Hyrien, T. R. Mosmann et al., “Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a “vaccinal effect” of rituximab,” Blood, vol. 113, no. 16, pp. 3809–3812, 2009.View at: Publisher Site | Google Scholar
S. Manzur, S. Cohen, J. Haimovich, and N. Hollander, “Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma,” Clinical and Experimental Immunology, vol. 170, pp. 291–299, 2012.View at: Google Scholar
S. J. Dovedi, M. H. Melis, R. W. Wilkinson et al., “Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma,” Blood, vol. 121, pp. 251–259, 2013.View at: Google Scholar
J. Honeychurch, M. H. Melis, S. J. Dovedi, L. Mu, and T. M. Illidge, “Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations,” Leukemia & Lymphoma, vol. 54, pp. 2008–2015, 2013.View at: Google Scholar
J. P. Leonard, B. K. Link, C. Emmanouilides et al., “Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non-Hodgkin's lymphoma,” Clinical Cancer Research, vol. 13, no. 20, pp. 6168–6174, 2007.View at: Publisher Site | Google Scholar
G. Salles, J. F. Seymour, F. Offner et al., “Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial,” The Lancet, vol. 377, pp. 42–51, 2011.View at: Google Scholar
M. Ghielmini, K. Rufibach, G. Salles et al., “Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK),” Annals of Oncology, vol. 16, no. 10, pp. 1675–1682, 2005.View at: Publisher Site | Google Scholar
J. J. Fournie, H. Sicard, M. Poupot et al., “What lessons can be learned from gammadelta T cell-based cancer immunotherapy trials?” Cellular & Molecular Immunology, vol. 10, pp. 35–41, 2013.View at: Google Scholar
M. S. Braza, A. Caraux, T. Rousset et al., “Gammadelta T lymphocytes count is normal and expandable in peripheral blood of patients with follicular lymphoma, whereas it is decreased in tumor lymph nodes compared with inflammatory lymph nodes,” The Journal of Immunology, vol. 184, no. 1, pp. 134–140, 2010.View at: Publisher Site | Google Scholar
H. Tokuyama, T. Hagi, S. R. Mattarollo et al., “V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs: rituximab and trastuzumab,” International Journal of Cancer, vol. 122, pp. 2526–2534, 2008.View at: Google Scholar
E. Kimby, “Biological therapy doublets: pairing rituximab with interferon, lenalidomide, and other biological agents in patients with follicular lymphoma,” Current Hematologic Malignancy Reports, vol. 7, pp. 221–227, 2012.View at: Google Scholar
C. W. Scholz, A. Pinto, W. Linkesch et al., “(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial,” Journal of Clinical Oncology, vol. 31, pp. 308–313, 2013.View at: Google Scholar
F. Morschhauser, J. Radford, A. Van Hoof et al., “Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma,” Journal of Clinical Oncology, vol. 26, no. 32, pp. 5156–5164, 2008.View at: Publisher Site | Google Scholar
F. Morschhauser, J. Radford, A. Van Hoof et al., “(90)Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7. 3 years from the International, Randomized, Phase III First-LineIndolent trial,” Journal of Clinical Oncology, vol. 31, pp. 1977–1983, 2013.View at: Google Scholar
N. M. Pennell, M. Cheung, L. K. Hicks et al., “First evidence for high incidence of complete and sustained molecular remissions and maintenance of immune responses in patients receiving consolidation with Y90 Ibritumomab Tiuxetan ((90)Y-RIT) post R-CHOP for newly diagnosed advanced stage high and intermediate risk follicular lymphoma,” Blood, vol. 118, Abstract 2701, 2011.View at: Google Scholar
F. Buchegger, C. Antonescu, C. Helg et al., “Long-term follow-up after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma: an update at 12 years,” Nuclear Medicine, vol. 52, p. A114, 2013, (Abstract).View at: Google Scholar
A. Lanzavecchia, S. Abrignani, D. Scheidegger, R. Obrist, B. Dorken, and G. Moldenhauer, “Antibodies as antigens. The use of mouse monoclonal antibodies to focus human T cells against selected targets,” Journal of Experimental Medicine, vol. 167, no. 2, pp. 345–352, 1988.View at: Google Scholar
R. Marcus, K. Imrie, P. Solal-Celigny et al., “Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma,” Journal of Clinical Oncology, vol. 26, no. 28, pp. 4579–4586, 2008.View at: Publisher Site | Google Scholar
W. Hiddemann, M. Kneba, M. Dreyling et al., “Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group,” Blood, vol. 106, no. 12, pp. 3725–3732, 2005.View at: Publisher Site | Google Scholar
M. Herold, A. Haas, S. Srock et al., “Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German study group hematology and oncology study,” Journal of Clinical Oncology, vol. 25, no. 15, pp. 1986–1992, 2007.View at: Publisher Site | Google Scholar
O. W. Press and M. C. Palanca-Wessels, “Selection of first-line therapy for advanced follicular lymphoma,” Journal of Clinical Oncology, vol. 31, pp. 1496–1497, 2013.View at: Google Scholar
M. J. Rummel, N. Niederle, G. Maschmeyer et al., “Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial,” The Lancet, vol. 381, pp. 1203–1210, 2013.View at: Google Scholar
I. W. Flinn, R. H. Van der Jagt, B. S. Kahl et al., “An open-label, randomized study of Bendamustine and Rituximab (BR) compared with Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CVP) or Rituximab, Cyclophoasphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in first-line tretment of patients with advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphomas (MCL). The Bright study,” Blood, vol. 120, Abstract 902, 2012.View at: Google Scholar
N. L. Berinstein, N. M. Pennell, M. A. Cussen et al., “Sustained immune compentency and long term molecular remissions in FL patients with FLIPI risk factors >1, treated front line with R-CHOP followed by consolidative (90)Y-radioimmunotherapy and maintenance rituximab,” Blood, vol. 120, Abstract 3681, 2012.View at: Google Scholar
T. E. Witzig, L. I. Gordon, F. Cabanillas et al., “Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 20, no. 10, pp. 2453–2463, 2002.View at: Publisher Site | Google Scholar
O. W. Press, J. M. Unger, L. M. Rimsza et al., “Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016,” Journal of Clinical Oncology, vol. 31, pp. 314–320, 2013.View at: Google Scholar
M. Ghielmini, U. Vitolo, E. Kimby et al., “ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL),” Annals of Oncology, vol. 24, pp. 561–576, 2013.View at: Google Scholar
P. L. Zinzani, M. Marchetti, A. Billio et al., “SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma,” American Journal of Hematology, vol. 88, pp. 185–192, 2013.View at: Google Scholar
J. Yared, A. Kimball, M. R. Baer, H. Bahrain, and M. Auerbach, “Rituximab maintenance therapy until progression after rituximab and chemotherapy induction in patients with follicular lymphoma,” Clinical Lymphoma Myeloma and Leukemia, vol. 13, pp. 253–257, 2013.View at: Google Scholar
T. W. Kelley and C. J. Parker, “CD4 (+)CD25 (+)Foxp3 (+) regulatory T cells and hematologic malignancies,” Frontiers in Bioscience, vol. 2, pp. 980–992, 2010.View at: Google Scholar
E. Derenzini, C. Pellegrini, R. Maglie et al., “Collection of hematopoietic stem cells after previous exposure to Yttrium-90 Ibritumomab Tiuxetan (Zevalin) is feasible and does not impair autologous stem cell transplantation outcome in follicular lymphoma,” Blood, vol. 120, Abstract 3019, 2012.View at: Google Scholar
J. M. Bennett, M. S. Kaminski, J. P. Leonard et al., “Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab,” Blood, vol. 105, no. 12, pp. 4576–4582, 2005.View at: Publisher Site | Google Scholar
D. Zimowska-Curylo, W. Jurczak, A. Giza, M. Jakobczyk, K. Krawczyk, and A. B. Skotnicki, “High incidence of tMDS in elederly lymphoma patients subjected to radioimmunotherapy,” Blood, vol. 120, Abstract 4882, 2012.View at: Google Scholar
S. Waheed, I. Ferreira, D. A. Katz et al., “Incidence and characteristics of therapy related myeloid neoplasms in patients with non-Hodgkins lymphoma treated with radioimmunotherapy,” Blood, vol. 2012, Abstract 4924, 2012.View at: Google Scholar
D. J. Kern, B. R. James, S. Blackwell, C. Gassner, C. Klein, and G. J. Weiner, “GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present,” Leukemia & Lymphoma, vol. 54, no. 11, pp. 2500–2505, 2013.View at: Google Scholar
M. S. Czuczman, J. P. Leonard, S. Jung et al., “Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB, 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness,” Annals of Oncology, vol. 23, pp. 2356–2362, 2012.View at: Google Scholar
B. W. Grant, S. H. Jung, J. L. Johnson et al., “A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB, 50701,” Cancer, vol. 119, pp. 3797–3804, 2013.View at: Google Scholar
E. Carlotti, D. Wrench, J. Matthews et al., “Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone,” Blood, vol. 113, no. 15, pp. 3553–3557, 2009.View at: Publisher Site | Google Scholar